Validation of hs-cTnI-Alinity in the early diagnosis of acute myocardial infarction

OBJECTIVES: It is unknown whether high-sensitivity cardiac troponin I (hs-cTnI) measured on the Alinity platform (hs-cTnI-Alinity), can be used with the same clinical decision values as the Architect platform (hs-cTnI-Architect). METHODS: In an international prospective study, hs-cTnI-Alinity and hs-cTnI-Architect were measured from the same blood samples obtained at 0 h, 1 h, and 2 h from patients presenting to the emergency department with acute chest discomfort. The final diagnosis was centrally adjudicated by two cardiologists. We tested four hypotheses: hs-cTnI-Alinity and hs-cTnI-Architect have (1) excellent analytical agreement, (2) high concordance at common analytical benchmarks (limit-of-detection and upper-reference-limit); (3) high diagnostic accuracy for AMI; and (4) comparable clinical performance for early rule-out and rule-in of AMI. RESULTS: Among 1,573 eligible patients (median age 60 years, 34.7 % women) 7,438 measurements of hs-cTnI-Alinity and hs-cTnI-Architect from the same samples were performed. The prevalence of AMI was 17.7 % (279/1,573). Analytical agreement between hs-cTnI-Alinity and hs-cTnI-Architect was excellent (mean bias -3.6 ng/L [95 % CI -17.3 to 10.1]). Using limit-of-detection and upper-reference-limit as benchmarks, agreement was high. However, major disagreement occurred in 2.5 %, including only one AMI. Diagnostic accuracy for AMI was very high and comparable between hs-cTnI-Alinity and hs-cTnI-Architect (area under the receiver-operating-characteristics curve 0.95 [95 % CI 0.95-0.96] and 0.96 [95 % CI 0.95-0.96]). Sensitivity for ruling-out AMI were >99 % and specificity >93 % and comparable between both assays when applying the ESC 0/1h and ESC 0/2h algorithm derived for hs-cTnI-Architect. CONCLUSIONS: Analytic benchmarks and ESC 0/1h and 0/2h algorithm cut-offs originally derived for hs-cTnI-Architect might be safely applied when using hs-cTnI-Alinity.

Authors

Institutions

Publication Details

Journal
Clinical Chemistry and Laboratory Medicine (CCLM)
Published
2026-10-27
DOI
https://doi.org/10.1515/cclm-2026-0959
Primary Topic
Acute Myocardial Infarction Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Validation of hs-cTnI-Alinity in the early diagnosis of acute myocardial infarction

Ivo Strebel, Koray Durak, Pedro López‐Ayala, Damian Kawecki et al.
Clinical Chemistry and Laboratory Medicine (CCLM)
Acute Myocardial Infarction Research
article

Validation of hs-cTnI-Alinity in the early diagnosis of acute myocardial infarction

Ivo Strebel, Koray Durak, Pedro López‐Ayala, Damian Kawecki, Michael Christ, Ksenija Slankamenac, Felix Mahfoud, KATHARINA M. RENTSCH, Luca Crisanti, Luca Koechlin, Angelika Hammerer‐Lercher, Jasper Boeddinghaus, Paolo Bima, Karin S. Wildi, Óscar Miró, Danielle Menosi Gualandro, Arnaud Tanguy Champetier, Christian Mueller, Emel Kaplan, Lourdes Herraiz Recuenco, Tzu-Ying Tsao, Lorenz Jackl, Mustafa Kron
article en

Abstract

OBJECTIVES: It is unknown whether high-sensitivity cardiac troponin I (hs-cTnI) measured on the Alinity platform (hs-cTnI-Alinity), can be used with the same clinical decision values as the Architect platform (hs-cTnI-Architect). METHODS: In an international prospective study, hs-cTnI-Alinity and hs-cTnI-Architect were measured from the same blood samples obtained at 0 h, 1 h, and 2 h from patients presenting to the emergency department with acute chest discomfort. The final diagnosis was centrally adjudicated by two cardiologists. We tested four hypotheses: hs-cTnI-Alinity and hs-cTnI-Architect have (1) excellent analytical agreement, (2) high concordance at common analytical benchmarks (limit-of-detection and upper-reference-limit); (3) high diagnostic accuracy for AMI; and (4) comparable clinical performance for early rule-out and rule-in of AMI. RESULTS: Among 1,573 eligible patients (median age 60 years, 34.7 % women) 7,438 measurements of hs-cTnI-Alinity and hs-cTnI-Architect from the same samples were performed. The prevalence of AMI was 17.7 % (279/1,573). Analytical agreement between hs-cTnI-Alinity and hs-cTnI-Architect was excellent (mean bias -3.6 ng/L [95 % CI -17.3 to 10.1]). Using limit-of-detection and upper-reference-limit as benchmarks, agreement was high. However, major disagreement occurred in 2.5 %, including only one AMI. Diagnostic accuracy for AMI was very high and comparable between hs-cTnI-Alinity and hs-cTnI-Architect (area under the receiver-operating-characteristics curve 0.95 [95 % CI 0.95-0.96] and 0.96 [95 % CI 0.95-0.96]). Sensitivity for ruling-out AMI were >99 % and specificity >93 % and comparable between both assays when applying the ESC 0/1h and ESC 0/2h algorithm derived for hs-cTnI-Architect. CONCLUSIONS: Analytic benchmarks and ESC 0/1h and 0/2h algorithm cut-offs originally derived for hs-cTnI-Architect might be safely applied when using hs-cTnI-Alinity.

Clinical Chemistry and Laboratory Medicine (CCLM)
Medical University of Silesia (PL), University of Basel (CH), University of Zurich (CH), University Hospital of Basel (CH), Landeskrankenhaus Feldkirch (AT), University Hospital of Zurich (CH), Hospital Clínic de Barcelona (ES), Luzerner Kantonsspital (CH), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Kantonsspital Aarau (CH), University of Turin (IT), Universitat de Barcelona (ES), Sapienza University of Rome (IT)
Good health and well-being
Openalex Percentile: Top 11%
Acute Myocardial Infarction Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon